For us longs out there, expect some decline today in AMRI in response to Aventis decline in sales of ALegra. WHile AMRI revenues may not show any decline due to this, the street continues to believe that AMRI profits are heavily related to this.
it is too bad to see the decline, though not really shocking, but the bottom line is with cash backed out amri sells for about 8 times earnings.
This news has been more than priced into the stock for over a year but that doesn't mean there won't be a negative reaction.
But the naysayers on the stock thought Allegra sales would be devestated this whole year and it has not happened.
It will be interesting to see how this is spun. Because those who are negative can say "aha, now the market sees the alternatives to allegra the the decline has just begun." Those who view it more positively will say, "claritan has been marketing its otc relentlessly and this is all the dent they could make? Not too impressive."
After all is said in done amri still is an amzing value as a stock and though it has been rather dull and challenged as a stock for some time I think the companies prospects will elevate the price inin the near future as pharmas ramp up spending.